Dopamine Preparation for Intravenous Infusion
Dopamine should be diluted in 5% dextrose or 0.9% sodium chloride to standard concentrations of 800 mcg/mL, 1600 mcg/mL, or 3200 mcg/mL, administered only via infusion pump through a large vein, and never mixed with alkaline solutions like sodium bicarbonate. 1
Dilution and Concentration
The FDA-approved preparation involves three standard concentrations 1:
- 800 mcg/mL (less concentrated): Preferred when fluid expansion is not a concern
- 1600 mcg/mL (moderate concentration): Standard preparation for most patients
- 3200 mcg/mL (most concentrated): Preferred in patients with fluid retention or when slower infusion rates are desired
Compatible diluents include 1, 2:
- 5% dextrose in water (D5W)
- 0.9% sodium chloride (normal saline)
- 5% dextrose in 0.45% sodium chloride
- 5% dextrose in lactated Ringer's solution
- Lactated Ringer's injection
Critical incompatibility: Never add sodium bicarbonate or any alkaline solution, as dopamine is inactivated in alkaline environments 1, 2. A 5% sodium bicarbonate-dopamine mixture produces an unstable solution with pH 8.20 and develops a pink color indicating chemical degradation 2.
Stability Considerations
Dopamine stability varies by diluent 3, 4:
- More stable in 5% glucose than 0.9% sodium chloride
- Up to 15% concentration loss can occur after 24 hours 4
- Solutions in glass bottles at pH ≤6.85 remain stable for at least 48 hours at room temperature 2
- When refrigerated at 5°C in 5% dextrose, stable for minimum 7 days 2
Important practice point: Prepare infusions 30 minutes before administration and replace every 12 hours rather than 24 hours to minimize concentration fluctuations that correlate with blood pressure variations 4.
Administration Guidelines
Route and access 1:
- Infuse into a large vein whenever possible (antecubital fossa preferred over hand/ankle veins)
- Avoid umbilical artery catheters
- Use only an infusion pump, preferably volumetric
- Never regulate by gravity and mechanical clamps alone
- Pediatric: 2-20 mcg/kg/min for cardiogenic/distributive shock, titrated to clinical effect
- Adult: Begin at 2-5 mcg/kg/min, increase in 5-10 mcg/kg/min increments up to 20-50 mcg/kg/min as needed
- Doses >50 mcg/kg/min may cause excessive vasoconstriction and ischemia 5
For refractory hypotension in anaphylaxis: 400 mg dopamine in 500 mL D5W, infused at 2-20 mcg/kg/min with continuous hemodynamic monitoring 6.
Labeling Requirements
Essential label information 1:
- Final concentration (mcg/mL)
- Diluent used
- Preparation date and time
- Expiration date/time (based on stability data)
- "Do not use if darker than slightly yellow or discolored"
- "Protect from light" (though light protection may not be critical for short-term use 3)
Critical Safety Warnings
Extravasation management 5:
- Extravasation causes severe skin injury and tissue necrosis
- Monitor infusion site continuously for free flow
- If extravasation occurs: inject phentolamine 0.1-0.2 mg/kg (up to 10 mg) diluted in 10 mL of 0.9% sodium chloride intradermally at the site
Visual inspection 1:
- Do NOT administer if solution is darker than slightly yellow
- Discard if any discoloration, cloudiness, or particulate matter present
- Ensure container is undamaged
Discontinuation 1:
- Gradually decrease dose while expanding blood volume with IV fluids
- Abrupt discontinuation may cause marked hypotension
Dose-Dependent Effects
Understanding receptor activity guides dosing 5:
- 1-5 mcg/kg/min: Dopaminergic and β-adrenergic effects predominate
- >5 mcg/kg/min: α-adrenergic vasoconstriction increases
- >20 mcg/kg/min: Risk of peripheral, renal, and splanchnic vasoconstriction/ischemia
Monitoring parameters 1:
- Blood pressure and heart rate continuously
- Urine output (decreasing output without hypotension warrants dose reduction)
- ECG for arrhythmias
- Signs of excessive vasoconstriction